Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05184816

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-27

35

Participants Needed

7

Research Sites

257 weeks

Total Duration

On this page

Sponsors

M

Memorial Sloan Kettering Cancer Center

Lead Sponsor

C

Center for Experimental Therapeutics

Collaborating Sponsor

AI-Summary

What this Trial Is About

The researchers are doing this study to find out whether deferoxamine (DFO) given intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal metastasis from solid tumor cancer. The researchers will test different doses of DFO to find the highest dose that causes few or mild side effects. When the dose is found, they will test it in future participants to see whether DFO is a safe and effective treatment for people with leptomeningeal metastasis from solid tumor malignancies. They are also doing this study to see how the body absorbs, distributes, gets rid of, and responds to DFO.

CONDITIONS

Official Title

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older at time of consent
  • ECOG performance status of 2 or less or Karnofsky score of 60 or higher
  • Life expectancy of at least 8 weeks as judged by the investigator
  • Leptomeningeal metastasis from any solid tumor diagnosed by positive cerebrospinal fluid tests or MRI evidence, including newly diagnosed, recurrent, or persistent disease
  • Confirmation of solid tumor malignancy by pathology report
  • Patients with stable or treated brain metastases are eligible
  • Patients with controlled seizure disorders on medication are eligible
  • Normal cerebrospinal fluid flow with no obstructive hydrocephalus or shunts
  • Patients with isolated brain disease progression and stable disease elsewhere may participate
  • Patients with both brain and body disease progression may be eligible depending on systemic therapy activity
  • Must have a functioning Ommaya reservoir or be a candidate for placement before first treatment
  • Adequate bone marrow and organ function as defined by blood tests or approved exemptions
  • Women of childbearing potential and sexually active males must use effective contraception during the study
Not Eligible

You will not qualify if you...

  • CNS-directed radiation therapy within 7 days before first dose
  • Receiving other treatments specifically for leptomeningeal metastasis that are controlling the disease
  • Contraindication to gadolinium-enhanced MRI
  • Use of systemic iron chelators within 4 weeks before first dose
  • Use of ascorbic acid or prochlorperazine within 2 weeks before first dose
  • Receiving whole-brain or craniospinal radiation during the study
  • Physical or psychiatric conditions that prevent compliance or tolerance of treatment
  • Women who are pregnant or breastfeeding
  • Known hypersensitivity to study treatment or components

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States, 07920

Actively Recruiting

2

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, United States, 07748

Actively Recruiting

3

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

4

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, United States, 11725

Actively Recruiting

5

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States, 10604

Actively Recruiting

6

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States, 10065

Actively Recruiting

7

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, United States, 11553

Actively Recruiting

Loading map...

Research Team

J

Jessica Wilcox, MD

CONTACT

A

Adrienne Boire, MD,PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis | DecenTrialz